{"id":21498,"date":"2025-06-24T08:30:00","date_gmt":"2025-06-24T06:30:00","guid":{"rendered":"https:\/\/vasro.de\/esg-investing-in-pharma-for-responsible-equity-portfolios\/"},"modified":"2025-06-14T20:04:04","modified_gmt":"2025-06-14T18:04:04","slug":"esg-investing-in-pharma-for-responsible-equity-portfolios","status":"publish","type":"post","link":"https:\/\/vasro.de\/en\/esg-investing-in-pharma-for-responsible-equity-portfolios\/","title":{"rendered":"ESG Investing in Pharma for Responsible Equity Portfolios"},"content":{"rendered":"\n

ESG investing in pharma enables investors to pursue equity strategies that combine financial returns with meaningful impact. Many see this approach as a catalyst for responsible innovation and stronger corporate behavior within the pharmaceutical sector. Recent research highlights the tangible benefits:<\/p>\n\n\n\n

Study & Sample<\/a><\/p><\/th>

Key Metrics<\/p><\/th>

Numerical Findings<\/p><\/th>

Implication<\/p><\/th><\/tr>

L\u00f3pez-Toro et al. (2021)<\/p><\/td>

30 Nasdaq U.S. Smart Pharmaceuticals Index companies<\/p><\/td>

ROA, ROE, Tobin’s Q<\/p><\/td>

Positive relationship between ESG indicators and financial ratios<\/p><\/td><\/tr>

Hakimi et al. (2023)<\/p><\/td>

813 European firms over 10 years<\/p><\/td>

ROA, Tobin’s Q<\/p><\/td>

Positive ESG effect on financial performance only if ESG score > 56.78%<\/p><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

\n

Over US$51 billion flowed into ESG funds in 2021<\/a>, representing one-quarter of all US stock funding. ESG-linked bonds now reward companies that expand medicine access or tackle global health challenges.<\/p>\n<\/blockquote>\n\n\n\n

ESG investing in pharma not only addresses sector-specific risks but also helps drive positive impact for both investors and society.<\/p>\n\n\n\n

Table of Contents<\/h2>